Navigation Links
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Date:3/8/2013

  • You take NSAIDs or a medicine to prevent blood from clotting
  • You have a history of difficult or repeated epidural or spinal punctures
  • You have a history of problems with your spine or have had surgery on your spine
  • If you take XARELTO® and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have tingling, numbness, or muscles weakness, especially in your legs and feet.

    WHO SHOULD NOT TAKE XARELTO®?

    Do not take XARELTO® if you:

    • Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO® if you currently have unusual bleeding.
    • Are allergic to rivaroxaban or any of the ingredients of XARELTO®.

    WHAT SHOULD I TELL MY DOCTOR BEFORE OR WHILE TAKING XARELTO®?

    Before taking XARELTO®, tell your doctor if you:

    • Have ever had bleeding problems
    • Have liver or kidney problems
    • Have any other medical condition
    • Are pregnant or plan to become pregnant. It is not known if XARELTO® will harm your unborn baby. Tell your doctor right away if you become pregnant while taking XARELTO®.  If you take XARELTO® during pregnancy, tell your doctor right away if you have bleeding or symptoms of blood loss.
    • Are breastfeeding or plan to breastfeed. It is not known if XARELTO® passes into your breast milk.  You and your doctor should decide if you will take XARELTO® or breastfeed.

    Tell all of your doctors and dentists that you are taking XARELTO®. They should talk to the doctor who prescri
    '/>"/>

    SOURCE Janssen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
    2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
    3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
    4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
    5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
    6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
    7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
    8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
    9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
    10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
    11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
    (Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
    (Date:1/22/2015)... UPI ), a medical device company that develops, ... dysfunctions, today reported financial results for the fiscal 2015 ... for the Company,s Urgent ®  PC Neuromodulation System grew ... as compared to $3.9 million in the third quarter ...
    Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
    ... 3 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that the Company has licensed to Targacept, ... patents and library of preclinical compounds that target the ...
    ... , SHANGHAI , ... Shanghai based,life science research service company, and Bio ... research service company, announced today the completion of,a ... The company is using the,funding to scale research & ...
    Cached Medicine Technology:Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 2Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 3Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 4Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 2Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 3
    (Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
    (Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
    (Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
    (Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
    (Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
    Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
    ... N.C., Dec. 14 Companies competing in a,regulated ... Organizations have come to rely on integrated quality ... effective quality systems,don,t just spontaneously spring up in ... creating and maintaining a quality operation that,functions across ...
    ... 14 HealthSouth,Corporation (NYSE: HLS ) today ... United States Department of Justice on behalf of ... of Health and Human,Services (HHS) to resolve issues ... team. The settlement amount of $14.2,million was previously ...
    ... WASHINGTON, Dec. 14 Following is a statement,by ... Healthcare Products,Association (CHPA), regarding the recommendations of the ... on phenylephrine:, "Phenylephrine 10 mg is safe ... proven effective for nasal decongestion in multiple clinical ...
    ... study finds , FRIDAY, Dec. 14 (HealthDay News) ... employees, a new U.S. study finds. , "People ... have healthier lifestyles. Individuals who perceive an increase in ... lifestyle changes," lead author Joseph G. Grzywacz, of Wake ...
    ... A new review article from the journal Dermatologic Therapy ... is now becoming used by dermatologists to treat various ... standard therapy in treating aggressive lymphomas, the drug rituximab ... off-label uses of rituximab in dermatology and found that ...
    ... COM, VANCOUVER, Dec. 14 /PRNewswire-FirstCall/ - Cardiome Pharma ... and,webcast will be held on Friday, December 14, 2007 ... the investor community., To access the conference call, ... dial-in line for analysts on which,we will respond to ...
    Cached Medicine News:Health News:Integrating Quality into Business Systems for High Performance, Complimentary Excerpt Available from Best Practices, LLC 2Health News:HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government 2Health News:Statement from the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose 2Health News:Workplace Flexibility Can Boost Healthy Behaviors 2Health News:Cardiome to Hold Investor Update Call 2Health News:Cardiome to Hold Investor Update Call 3Health News:Cardiome to Hold Investor Update Call 4
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: